Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

BK7508 Pharmaceutical Companies

Trading 04-27 14:02:00 AEST

535.81

+3.21

+0.60%

High536.59	Low531.02	Vol42.97M
Open531.52	D1 Closing532.60	Amplitude1.04%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O60.15M	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":535.8081,"timestamp":1777262519374,"preClose":532.60126,"halted":0,"volume":42974516,"delay":0,"changeRate":0.006021,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":3.206848,"latestTime":"04-27 14:02:00 AEST","open":531.5191,"high":536.58856,"low":531.02405,"amount":60146681,"amplitude":0.010448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777269600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1777248000000,1777269600000]],"turnoverRate":0.001672,"increases":7,"decrements":18,"flats":18,"marketCap":72901238758,"floatMarketCap":70095827884.9375},"requestUrl":"/m/hq/s/BK7508/wiki","defaultTab":"wiki","newsList":[{"id":"2630554793","title":"BUZZ-Australia's Clinuvel Pharmaceuticals slips after Jefferies cuts target price on trial setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2630554793","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630554793?lang=en_us&edition=fundamental","pubTime":"2026-04-27 10:58","pubTimestamp":1777258701,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clinuvel Pharmaceuticals slips after Jefferies cuts target price on trial setback** Shares of Clinuvel Pharmaceuticals CUV.AX fall as much as 1.2% to A$8.93** Jefferies cuts biopharma co's PT to A$39.2 from A$40.5, maintains \"buy\" rating ** Brokerage flags regulatory snags and delays in clinical trials for vitilgo, an autoimmune disease that affects the skin; phase 3 study of treatment to begin in 2HCY26** Expects revenue from treatment in 2HFY29 from FY28 predicted earlier, cuts FY28 EPS estimate by about 45%** All seven analysts rate stock \"buy\" or higher; median PT is A$23.29 - LSEG-compiled data** YTD, stock down 27.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL6N41A063:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630355391","title":"BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630355391","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630355391?lang=en_us&edition=fundamental","pubTime":"2026-04-27 10:35","pubTimestamp":1777257305,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement** Paradigm Biopharmaceuticals PAR.AX slips as much as 17.8% to A$0.185, lowest since September 26, 2024** Drug developer anno","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL6N41A05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630035854","title":"BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630035854","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630035854?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:36","pubTimestamp":1777253761,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln PlacementApril 27 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:COMPLETES A$14.0 MILLION PLACEMENTPLACEMENT AT AN ISSUE PRICE OF A$0.19 PER SHAREFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630215330","title":"BRIEF-Clinuvel Pharmaceuticals Says FDA Relaxes Scenesse Postmarketing Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630215330","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630215330?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:22","pubTimestamp":1777252921,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Says FDA Relaxes Scenesse Postmarketing RequirementApril 27  - Clinuvel Pharmaceuticals Ltd CUV.AX:FDA RELAXES SCENESSE POSTMARKETING REQUIREMENTQT STUDY REMOVED FROM U.S. POST-AUTHORIZATION REQUIREMENTS FOR SCENESSEFurther company coverage: CUV.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUE5ZMBJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337676","title":"Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337676","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630337676?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:36","pubTimestamp":1777250204,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said the US Food and Drug Administration  removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["POST","BK7508","BK4588","BK4585","BK4212","BK7067","CUV.AU","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337859","title":"Immutep Says Bank of New York Mellon Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337859","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630337859?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:21","pubTimestamp":1777249274,"startTime":"0","endTime":"0","summary":"Immutep  received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 21.11% from 20.08%, according to a Monday filing with the Australian bourse.Bank of New York Mellon and its affiliates now owns over 311 million shares in the company, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4559","BK4135","LU1699723380.USD","LU1571399168.USD","BK7508","LU0130517989.USD","BK4585","LU1201861249.SGD","BK7067","LU0477156953.USD","LU0130102774.USD","BK4588","LU0980610538.SGD","LU0648001328.SGD","IMM.AU","BK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630333203","title":"Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2630333203","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630333203?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:14","pubTimestamp":1777248895,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency  has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7129","BK7067","CUV.AU","BK4081","EMA","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630733225","title":"Paradigm Biopharmaceuticals - Placement at an Issue Price of a$0.19 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2630733225","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630733225?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630332250","title":"Paradigm Biopharmaceuticals - Completes a$14.0 Mln Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332250","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630332250?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248430,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630533105","title":"Clinuvel Pharmaceuticals Ltd-FDA Relaxes Scenesse Postmarketing Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630533105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630533105?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:42","pubTimestamp":1777243353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUE5ZMBJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331016","title":"Clinuvel Pharmaceuticals Ltd - Qt Study Removed From U.S. Post-Authorization Requirements for Scenesse","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331016?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:42","pubTimestamp":1777243353,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUE5ZMBJ3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630433143","title":"Noxopharm Ltd-Innovative Collaboration Further Expands Sofra Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2630433143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630433143?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:21","pubTimestamp":1777242111,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUE6X2JC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","NOX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331928","title":"ASX Growth Leaders With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331928","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331928?lang=en_us&edition=fundamental","pubTime":"2026-04-27 03:08","pubTimestamp":1777230494,"startTime":"0","endTime":"0","summary":"As the Australian share market shows resilience with a +0.4% advance amidst global uncertainties, particularly contrasting Wall Street's downturn, investors are keenly observing how local factors such as potential interest rate changes influence trading sentiment. In this environment, companies with high insider ownership often attract attention for their perceived alignment of interests between management and shareholders, making them notable candidates for those seeking growth opportunities...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","REG.AU","BK7095","TLX","BK7096","SKS.AU","XAO.AU","XJO.AU","BK7508","EIQ.AU","FRS.AU","AMI.AU","BK7113","BK7023","BK4139","TTT.AU","TLX.AU","BK7110","AR1.AU","BK7104","AV1.AU","IMA.AU","SPL.AU","MAU.AU","BK7506","BK7036","BK7016","BK7067","XKO.AU","TOR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319133","title":"ASX Penny Stocks To Watch In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319133","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630319133?lang=en_us&edition=fundamental","pubTime":"2026-04-27 03:02","pubTimestamp":1777230140,"startTime":"0","endTime":"0","summary":"As Australian shares edge up with a 0.4% advance, the market is showing resilience amid global uncertainties and potential interest rate decisions. In this climate, investors often turn their attention to penny stocks—companies that may be smaller or newer but can offer intriguing opportunities when backed by solid financials. Despite their vintage name, these stocks continue to capture interest for their potential to uncover hidden value and growth prospects in the ever-evolving market...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/retail/asx-aby/adore-beauty-group-shares/news/asx-penny-stocks-to-watch-in-april-2026-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/retail/asx-aby/adore-beauty-group-shares/news/asx-penny-stocks-to-watch-in-april-2026-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AEF.AU","IRI.AU","BK7049","GWA.AU","BK7016","BK7062","OBM.AU","BK7088","BK7094","BK7128","BK7058","BK7104","RPL.AU","BK7096","BK7095","BK7508","MVP.AU","PPS.AU","EDU.AU","ABY.AU","WC8.AU","BK7132","LBL.AU","BK7506","BK7503","BK7012","CGS.AU","CLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630980518","title":"How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2630980518","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630980518?lang=en_us&edition=fundamental","pubTime":"2026-04-25 20:10","pubTimestamp":1777119025,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals recently reported that the European Medicines Agency issued final scientific advice on its planned pivotal Phase III CUV107 trial, outlining how SCENESSE (afamelanotide) will be evaluated as a systemic treatment for non-segmental vitiligo in adults and adolescents.\nThe regulator’s “totality of evidence” approach, with T-VASI50 as the primary endpoint and strong emphasis on patient-reported and photographic outcomes, underscores both the complexity and patient-centric...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EMA","CUV.AU","BK4587","BK4211","BK4588","BK4551","BK7508","BK4081","AIYY","AI","BK4528","BK4585","BK4543","AIPO","ISBC","AGIX","ARTY","CHAT","BK4023","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630874424","title":"Carlisle Companies Q1 Margin Pullback Tests Long Term Expansion Thesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2630874424","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630874424?lang=en_us&edition=fundamental","pubTime":"2026-04-25 13:12","pubTimestamp":1777093945,"startTime":"0","endTime":"0","summary":"Carlisle Companies (CSL) opened 2026 with Q1 revenue of US$1,052.1 million and basic EPS of US$3.13, setting the tone for how the rest of the year might shape up for margin focused investors. Over recent quarters the company has seen revenue move from US$1,095.8 million and EPS of US$3.16 in Q1 2025 to a peak of US$1,449.5 million with EPS of US$5.93 in Q2 2025, before stepping down to US$1,052.1 million and EPS of US$3.13 in the latest quarter as attention shifts firmly to how consistently...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-q1-margin-pullback-tests-long-term-expans","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-q1-margin-pullback-tests-long-term-expans","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1169589451.USD","LU0728928796.USD","CSL.AU","LU1169590202.USD","BK4086","BK7067","BK7501","BK7511","SG9999004303.SGD","BK7508","CSL","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630878521","title":"Hexcel (HXL) Q1 EPS Swings Test Bullish Earnings Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2630878521","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630878521?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:07","pubTimestamp":1777064821,"startTime":"0","endTime":"0","summary":"Hexcel (HXL) opened Q1 2026 with revenue of US$501.5 million and basic EPS of US$0.49, setting the tone for how investors are reading the new earnings season. The company has seen quarterly revenue range from US$456.5 million in Q1 2025 to US$491.3 million in Q4 2025, while basic EPS moved between US$0.17 in Q2 2025 and US$0.60 in Q4 2025. This gives a clear view of how the top and bottom lines have tracked into this latest print. With that backdrop, the key question now is whether current...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-q1-eps-swings-test-bullish-earnings-growth-narrat","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-q1-eps-swings-test-bullish-earnings-growth-narrat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4112","LU0240877869.USD","LU0205194284.USD","BK4187","LU0205193047.USD","BLSG","LU0053671581.USD","HXL","BK7508","BK7067","BLSX","LU0240878834.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629828100","title":"Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2629828100","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629828100?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:48","pubTimestamp":1777042080,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were tracking higher Friday morning, rising 0.72% to 2,771.65 on the S&P Asia 50 ADR Index, which has fallen more than 2.5% for the week so far.From North Asia, the gainers were led by semiconductor firm ASE Technology  and internet and data center services provider VNET Group , which climbed 6.8% and 4.1% respectively. They were followed by computer hardware maker Canaan , which advanced 2.5%.The decliners from North Asia were led by LexinFintech  and Four Seasons Education , which shed 9.3% and 8.9% respectively. They were followed by financial firm Nomura  and 51Talk Online Education Group , which fell 5.6% and 4.9% respectively.From South Asia, the gainers were led by tech conglomerate Sea , which rose 1.2%, followed by pharmaceutical company Dr. Reddy's Laboratories  and lender HDFC Bank , which were up 0.7% and 0.2% respectively.The decliners from South Asia were led by telecommunications operator Telekomunikasi Indo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RDY","LU0890818403.SGD","BK7095","LU2152927971.USD","LU1267930656.SGD","LU1105468828.SGD","LU0536402901.SGD","SG9999014013.SGD","LU0823038988.USD","LU0251143029.SGD","SG9999004360.SGD","LU0345776255.USD","LU0831103253.SGD","COE","LU2226246903.HKD","SG9999002406.SGD","IE00B0JY6M65.USD","LU0499858602.USD","LU1791710582.SGD","LU0197773673.USD","SG9999004220.SGD","AIA","LU0048575426.USD","LU0868486357.SGD","SG9999001135.SGD","BK4533","IE00B3M56506.USD","SG9999006266.SGD","LU0231203729.USD","HDB","LU0572939691.SGD","LU2360107671.USD","SG9999014005.SGD","LU0456842615.SGD","LU0287143357.SGD","LU0251143458.SGD","LU0175139822.USD","LU0431992006.USD","BK4207","LU1235295612.USD","LU0261945553.USD","LU1102505762.USD","LU1804176565.USD","LU0348788117.USD","SG9999002604.SGD","LU1282648689.USD","IE0034224299.USD","LU1854104046.USD","BK7039","LU0181495838.USD","BK4554","LU1046422090.SGD","BK4532","BK4585","CAN","BK4543","LU0516423174.USD","LU1861217088.USD","NMR","BK4166","BK4600","BK4506","LU0516422366.SGD","BK7502","LU1102505929.USD","LU2238330802.EUR","LU2125910500.SGD","LU0441851309.USD","BK4107","BK4588","FEDU","SG9999005177.SGD","LU0197773160.USD","LU0261950470.USD","IBN","LU1048588211.SGD","TLK","SG9999013460.SGD","LU0072462343.USD","LU0307460401.USD","LU0898667661.SGD","LU2125910849.SGD","LU1770036033.HKD","IE0001KFT4U8.USD","BK4127","BK4503","BK4579","IE0031814969.USD","BK4116","LU2065171311.SGD","BK4523","LU1481012133.USD","BK4134","SG9999014039.USD","LU0066902890.USD","LU0589944569.HKD","SG9999002620.SGD","LU2663582299.SGD","BK4117","LU0828237940.HKD","SG9999014484.SGD","LU0791590937.USD","BK7016","LU2045819591.USD","BK7096","LU0737861269.HKD","LU1791710400.SGD","LU0823039010.USD","LU0333810181.USD","BK4526","LU0531971678.HKD","LU0918141705.HKD","LU0049112450.USD","BK4595","SG9999013486.USD","LU0143863784.USD","LU1868837722.USD","LU2087589342.USD","BK4220","LU0289960550.SGD","LU2008162690.USD","LU2543165471.USD","BK4581","LU0348816934.USD","LU0708995666.HKD","BK4170","LU0630378429.USD","LU1861220207.SGD","LU0210637038.USD","LU0390134368.USD","LU0197229882.USD","LU1048596156.SGD","LU0164881194.USD","LU2065171402.SGD","LX","BK4204","LU0918141887.USD","BK4552","BK7506","LU2065169927.USD","BK4551","LU1242518931.SGD","LU1868838027.USD","LU1839390173.USD","INFY","BK4085","LU0248272758.USD","LU1366334651.USD","SG9999002414.USD","BK4548","SGXZ58947870.SGD","BK4115","BK4557","BK4535","LU0516422952.EUR","LU0348814723.USD","LU1508157978.USD","IE00B7N09G41.SGD","LU1868837565.USD","LU2265009873.SGD","ASX","LU0791591158.USD","LU0532188223.SGD","LU0348744763.USD","BK7508","IE00BYTNYM70.SGD","LU0630378692.HKD","LU0264606111.USD","LU2279701549.SGD","LU1805238398.USD","LU0528227936.USD","SG9999013478.USD","LU0345775950.USD","LU0516423091.SGD","LU0516422440.USD","LU0541502299.USD","BK4596","LU0143863198.USD","LU0541501648.USD","BK4141","LU0979878070.USD","LU1242518857.USD","BK4607","SG9999002679.SGD","SG9999014492.USD","LU0499858438.USD","LU1366334578.USD","BK4007","LU0797268264.HKD","LU2177674079.SGD","LU0264410563.USD","BK4566","LU0821914370.USD","LU2065170008.USD","BK4531","LU0862451753.SGD","LU0572940350.SGD","SE","IE00BD6J9T35.USD","LU1323998911.USD","LU1854103824.USD","SG9999014021.USD","LU0048573645.USD","VNET"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629817942","title":"NewMarket (NEU) Margin Decline Challenges Bullish Narratives After Strong Q1 EPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2629817942","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629817942?lang=en_us&edition=fundamental","pubTime":"2026-04-24 17:13","pubTimestamp":1777021991,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) opened 2026 with Q1 revenue of US$669.7 million and basic EPS of US$12.62, setting the tone for how the year might shape up against its recent track record. Over the past year, the company has seen trailing twelve month revenue sit at about US$2.7 billion and basic EPS at US$43.77, giving investors a clearer view of the earnings power behind the latest quarterly print. With a trailing net profit margin of 15.2% compared with last year’s 17.2%, the story this quarter is focused...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-bullish-narratives-a","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-bullish-narratives-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7508","NEU","BLSG","BK4109","BK4112","BLSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629689980","title":"Clinuvel plans Phase III CUV107 vitiligo trial of Scenesse plus NB-UVB vs NB-UVB","url":"https://stock-news.laohu8.com/highlight/detail?id=2629689980","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629689980?lang=en_us&edition=fundamental","pubTime":"2026-04-24 11:46","pubTimestamp":1777002368,"startTime":"0","endTime":"0","summary":"Clinuvel received final European Medicines Agency scientific advice on design of pivotal Phase III CUV107 study testing SCENESSE as systemic treatment for non-segmental vitiligo.Trial results have not been presented; study is slated to start in 2H 2026.CUV107 will compare SCENESSE used with narrowband UVB therapy versus narrowband UVB alone in 300 patients.EMA signaled it will weigh overall clinical package, including patient-reported assessments, when judging whether repigmentation benefits support marketing authorization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL59dwNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0179},{"period":"1month","weight":0.0221},{"period":"3month","weight":-0.0107},{"period":"6month","weight":0.0114},{"period":"1year","weight":0.1408},{"period":"ytd","weight":-0.0086}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"name":"BK7508","nameEN":"BK7508"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmaceutical Companies,BK7508,Pharmaceutical Companies股票,Pharmaceutical Companies股票老虎,Pharmaceutical Companies股票老虎国际,Pharmaceutical Companies行情,Pharmaceutical Companies股票行情,Pharmaceutical Companies股价,Pharmaceutical Companies股市,Pharmaceutical Companies股票价格,Pharmaceutical Companies股票交易,Pharmaceutical Companies股票购买,Pharmaceutical Companies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction